From Motley Fool:
No cholesterol drug is likely to ever reach the sales level that Lipitor was able to achieve, but investors can still profit buying stock in companies developing drugs for patients with high cholesterol where Lipitor or other statins aren’t enough to bring patients’ cholesterol levels down. Three drugs, in particular, are all poised to progress their cholesterol drugs in 2017.